Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma

Cancer

Volumn 121, Issue 20, 2015, Pages 3600-3611

  Qian, Guoqing ^a   Jiang, Ning ^a   Wang, Dongsheng ^a   Newman, Scott ^b   Kim, Sungjin ^b   Chen, Zhengjia ^b   Garcia, Gabriela ^c   MacBeath, Gavin ^c   Shin, Dong M ^a   Khuri, Fadlo R ^a   Chen, Zhuo G ^a   Saba, Nabil F ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c MERRIMACK PHARMACEUTICALS   (United States)

Author keywords

epidermal growth factor receptor (EGFR); head and neck cancer; heregulin; human epidermal growth factor receptor 3 (HER3); human papillomavirus

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2 PROTEIN, HUMAN; ERBB3 PROTEIN, HUMAN; GENETIC MARKER; NRG1 PROTEIN, HUMAN; P16 PROTEIN, HUMAN; TUMOR PROTEIN;

ARTICLE; CANCER CLASSIFICATION; CANCER GENETICS; CANCER PROGNOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DIMERIZATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY; TUMOR INVASION; GENETIC MARKER; GENETICS; HEAD AND NECK TUMOR; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS;

CARCINOMA, SQUAMOUS CELL; GENETIC MARKERS; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM PROTEINS; NEUREGULIN-1; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84943580009     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29549     Document Type: Article

References (48)

1. Siegel R, Ma J, Zou Z, Jemal A,. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
2. Saba NF, Goodman M, Ward K, et al., Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral tongue, base of tongue, and tonsils: a Surveillance, Epidemiology and End Results program-based analysis. Oncology. 2011; 81: 12-20.
3. Chaturvedi AK, Engels EA, Pfeiffer RM, et al., Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011; 29: 4294-4301.
4. D'Souza G, Dempsey A,. The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med. 2011; 53 (suppl 1): S5-S11.
5. Gillison ML, Koch WM, Capone RB, et al., Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000; 92: 709-720.
6. Haddad RI, Shin DM,. Recent advances in head and neck cancer. N Engl J Med. 2008; 359: 1143-1154.
7. Ang KK, Harris J, Wheeler R, et al., Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363: 24-35.
8. O'Sullivan B, Huang SH, Siu LL, et al., Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol. 2013; 31: 543-550.
9. Yarden Y,. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001; 37 (suppl 4): S3-S8.
10. Dhomen NS, Mariadason J, Tebbutt N, Scott AM,. Therapeutic targeting of the epidermal growth factor receptor in human cancer. Crit Rev Oncog. 2012; 17: 31-50.
11. Vlacich G, Coffey RJ,. Resistance to EGFR-targeted therapy: a family affair. Cancer Cell. 2011; 20: 423-425.
12. Mendelsohn J,. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol. 2002; 2D (suppl 18): 1S-13S.
13. Hansen AR, Siu LL,. Epidermal growth factor receptor targeting in head and neck cancer: have we been just skimming the surface? J Clin Oncol. 2013; 31: 1381-1383.
14. Licitra L, Storkel S, Kerr KM, et al., Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer. 2013; 49: 1161-1168.
15. Kong CS, Narasimhan B, Cao H, et al., The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2009; 74: 553-561.
16. Kumar B, Cordell KG, Lee JS, et al., EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 2008; 26: 3128-3137.
17. Hong A, Dobbins T, Lee CS, et al., Relationships between epidermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer. Eur J Cancer. 2010; 46: 2088-2096.
18. Romanitan M, Nasman A, Munck-Wikland E, Dalianis T, Ramqvist T,. EGFR and phosphorylated EGFR in relation to HPV and clinical outcome in tonsillar cancer. Anticancer Res. 2013; 33: 1575-1583.
19. Spangle JM, Munger K,. The HPV16 E6 oncoprotein causes prolonged receptor protein tyrosine kinase signaling and enhances internalization of phosphorylated receptor species. PLoS Pathog. 2013; 9: e1003237.
20. Breuleux M,. Role of heregulin in human cancer. Cell Mol Life Sci. 2007; 64: 2358-2377.
21. Jones JT, Akita RW, Sliwkowski MX,. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett. 1999; 447: 227-231.
22. Pinkas-Kramarski R, Shelly M, Guarino BC, et al., ErbB tyrosine kinases and the 2 neuregulin families constitute a ligand-receptor network. Mol Cell Biol. 1998; 18: 6090-6101.
23. Yarden Y, Sliwkowski MX,. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2: 127-137.
24. Citri A, Skaria KB, Yarden Y,. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res. 2003; 284: 54-65.
25. Yonesaka K, Zejnullahu K, Okamoto I, et al., Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011; 3: 99ra86.
26. Zhang L, Castanaro C, Luan B, et al., ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models. Mol Cancer Ther. 2014; 13: 1345-1355.
27. Jiang N, Wang D, Hu Z, et al., Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma. Mol Cancer Ther. 2014; 13: 1826-1836.
28. Shames DS, Carbon J, Walter K, et al., High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck. PLoS One. 2013; 8: e56765.
29. Liu J, Ray-Coquard IL, Selle F, et al., A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ERBB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers [abstract]. J Clin Oncol. 2014; 32 (suppl):Abstract 5519.
30. Higgins MJ, Doyle C, Paepke S, et al., A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ERBB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer [abstract]. J Clin Oncol. 2014 32 (suppl):Abstract 587.
31. Sequist LV, Lopez-Chavez A, Doebele RC, et al., A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib, in EGFR wild-type NSCLC patients [abstract]. J Clin Oncol. 2014; 32 (suppl):Abstract 8051.
32. Von Pawel J, Tseng J, Dediu M, et al., Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs) [abstract]. J Clin Oncol. 2014; 32 (suppl):Abstract 8045.
33. MacBeath G, Adiwijaya B, Liu J, et al., A meta-analysis of biomarkers in 3 randomized, phase 2 studies of MM-121, a ligand-blocking anti-ErbB3 antibody, in patients with ovarian, lung, and breast cancers. Ann Oncol. 2014; 25: iv58-iv84.
34. Onsum MD, Geretti E, Paragas V, et al., Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients. Am J Pathol. 2013; 183: 1446-1460.
35. Cerami E, Gao J, Dogrusoz U, et al., The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2: 401-404.
36. National Cancer Institute. Available at: https://wiki.nci.nih.gov/display/TCGA/RNASeq+Version+2. Accessed May 9, 2013.
37. Lewis JS Jr,. p16 immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol. 2012; 6 (suppl 1): S75-S82.
38. Gregory CW, Whang YE, McCall W, et al., Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res. 2005; 11: 1704-1712.
39. Khan AJ, King BL, Smith BD, et al., Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res. 2002; 8: 540-548.
40. Fountzilas G, Angouridakis N, Wirtz RM, Claas S, Nikolaou A, Kalogeras KT,. Prognostic value of VEGFC, HER2 and HER3 gene expression in recurrent squamous cell head and neck tumors. J Clin Oncol. 2006; 24 (suppl):Abstract 5538.
41. Takikita M, Xie R, Chung JY, et al., Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma. J Transl Med. 2011; 9: 126.
42. Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E,. HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst. 2013; 105: 266-273.
43. Lee CY, Lin Y, Bratman SV, et al., Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation. Cancer Res. 2014; 74: 341-352.
44. Sollome JJ, Thavathiru E, Camenisch TD, Vaillancourt RR,. HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4). Cell Signal. 2014; 26: 70-82.
45. Xia W, Petricoin EF 3rd, Zhao S, et al., An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. Breast Cancer Res. 2013; 15: R85.
46. Husain H, Psyrri A, Markovic A, et al., Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma. Laryngoscope. 2012; 122: 2762-2768.
47. Pogorzelski M, Ting S, Gauler TC, et al., Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy. Cell Death Dis. 2014; 5: e1091.
48. Sudaka A, Saada E, Natale R, et al., Differential expression of EGFR, HER2, P16, and high-risk (hr) HPV status in oropharyngeal (Or) and oral cavity (OC) squamous cell carcinoma (SCC) [abstract]. J Clin Oncol. 2012; 30 (suppl):Abstract 5521.